Clinical Trial

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Study acronym: FLY
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-03-18; most recent amendment 2026-03-17.
Status change: Not Yet Recruiting → Recruiting 2024-12-18
Trial Details
NCT Number NCT06328608
Lead Sponsor Chiesi Farmaceutici S.p.A.
Collaborators: ICON plc
Conditions Fabry Disease
Enrollment 22 participants
Start Date 2025-07-29
Primary Completion 2028-10 (estimated)
Study Completion 2031-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-10